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WS21.1 Recruitment and retention of newborn screened (NBS) infants
to an observational study with invasive outcome measures
J. Chudleigh1,2, A. Prasad1, J. Stocks2. 1Great Ormond Street Hospital for
Children, Respiratory Medicine, London, United Kingdom; 2UCL Institute of Child
Health, Portex Unit, London, United Kingdom
Objectives:
1. Assess feasibility of recruiting and retaining
a. NBS infants with CF to an invasive observational study involving pulmonary
function tests (PFTs), CT and bronchoscopy,
b. healthy controls (HC) to a longitudinal study of PFTs.
2. Investigate parental attitudes to participating in such a study.
Methods: PFTs were undertaken at 3 mths and 1 yr in both CF and healthy infants
between Jan 2010-Dec 2011. CT and bronchoscopy was also undertaken in those
with CF at 1 yr. Parental Attitude Questionnaires (PAQ) were administered to all
parents at the 3mth PFT. A further questionnaire was completed anonymously by
parents of CF infants following the 1 yr assessments.
Results: Of 107 eligible CF infants, 79% (84) attended the 3 mth PFT. By Dec 2011,
72 were at least 1 yr of age, of whom 90% (65) completed the 1 yr assessments.
Of the 270 HC invited to participate, 21% (56) had PFTs at 3mth. By Dec 2011,
46 were at least 1 yr of age, of whom 78% (36) completed PFTs.
Responses from the PAQ indicated that most parents of infants with CF chose to
be involved in the study to help their own and other infants in the future. Parents
of HC cited altruistic reasons. Most (95%) parents of CF infants would recommend
involvement in research to other parents.
Conclusions: Recruitment and retention of infants with CF was excellent, providing
encouraging data for future interventional trials. While recruitment of HC was
more difﬁcult, retention was similar. Parental attitudes were very positive, with the
majority of parents willing to be involved in such studies for the good of their own
and other children.
WS21.2 Newborn screening for cystic ﬁbrosis with an
IRT-PAP protocol
J. Hammermann1, L. Mense1, M. Stopsack2. 1Cystic Fibrosis Center, University
Hospital Carl Gustav Carus, Department of Pediatrics, Dresden, Germany;
2Institute for Clinical Chemistry, University Hospital Carl Gustav Carus, Dresden,
Germany
Background: In Dresden cystic ﬁbrosis newborn screening for the region of eastern
saxony is performed since 16 years now. The screening protocol has been changed
from an IRT-DNA screening to an IRT-PAP screening in January 2008.
Methods: IRT measurement was done with AutoDELFIA Kit (PerkinElmer Turku).
PAP measurement with MucoPAP Kit (DYNABIO Marseille). Blood samples
taken 36 to 72h after birth, gestational age >32 weeks, were tested for IRT.
For samples exceeding 50 ng/ml PAP measurement was added. All newborns with
result combinations IRT 50 ng/ml and PAP 1.8 ng/ml or IRT 100 ng/ml and
PAP 1.0 ng/ml or those with IRT 99.9th percentile alone were referred to
pilocarpin iontophoresis, clinical examination and stool elastase testing.
Results: By screening nearly 60 000 babies, we detected 11 patients with the
diagnose of cystic ﬁbrosis. In all cases the diagnose could be conﬁrmed by sweat
testing and genetics. Median Time until diagnose conﬁrmation was 47 days. 3
children had meconium ileus. In one child with meconium ileus screening was
false negative with a low PAP (0.7 ng/ml). In another case only IRT was elevated
over the 99.9th percentile (148.9 ng/ml), PAP was normal (0.9 ng/ml).
Conclusion: IRT-PAP measurement has shown to be a good alternative to IRT-DNA
screening for the detection of cystic ﬁbrosis patients. To ﬁnd the ideal PAP cut-off
level further investigation in a bigger population has do be done.
WS21.3 Cystic ﬁbrosis newborn screening protocols (IRT/IRT and
IRT/DNA) comparison
Z. Kusova1, N. Kashirskaya1, N. Petrova1, T. Vasilyeva1, N. Kapranov1. 1Research
Centre for Medical Genetics, Russian Academy of Medical Sciences, Moscow,
Russian Federation
Objectives: The aim − to estimate the reliability of two different cystic ﬁbrosis
(CF) newborn screening protocols: IRT/IRT and IRT/DNA.
Methods: All the results of neonatal screening for CF (IRT/IRT) in Moscow
were analyzed (June 1, 2006 − Dec 31, 2011). Additionally 1260 newborns with
high ﬁrst IRT-test (from all neonates born in 2008) were analyzed on 11 CFTR
mutations (CFTRdele2,3(21kb), F508del, Idel507, 1677delTA, 2184insA, 2143delT,
2183AA>G, 2184delA, 394delTT, 3821delT, L138ins − 69.5% of all).
Results: During the study period 557,344 neonates were screened, 64 children
with cystic ﬁbrosis were identiﬁed, giving an incidence of CF in Moscow as one in
8708 neonates. Our study showed, that CF newborn screening protocol IRT/IRT is
sensitive (Sn = 96.77%) and speciﬁc test (Sp = 99.82%), positive predictive value
(+PV) of IRT/IRT-test is 0.00332, likelihood ratio (LR) − 537:1, rate of false positive
results after the ﬁrst IRT test is 0.01035 (1:97), after retest − 0.00178 (1:558), and
value of false negative results of the IRT/IRT is 3% (0.03). Comparative analysis
of IRT/IRT and IRT/DNA tests showed, that IRT/DNA test is more sensitive (Sn =
100%), value of false positive [0.000344 (1:2901)] and false negative results of
IRT/DNA protocol is lower.
Conclusion: The incidence of CF in Moscow is one in 8708 neonates. The protocol
IRT/DNA is more sensitive then IRT/IRT in Russian population (Moscow).
WS21.4 Newborn screening for cystic ﬁbrosis in Switzerland −
evaluation after one year
J. Barben1, S. Gallati2, R. Fingerhut3, M.H. Schoeni4, C. Kuehni5,
M. Baumgartner6, T. Torresani3. 1Children’s Hospital, Dept. of Pulmonology,
St. Gallen, Switzerland; 2University Children’s Hospital, Division of Human
Genetics, Berne, Switzerland; 3University Children’s Hospital, Swiss Newborn
Screening Laboratory, Zu¨rich, Switzerland; 4University Children’s Hospital,
Outpatient Department, Berne, Switzerland; 5University of Berne, Institute of
Social and Preventive Medicine, Berne, Switzerland; 6University Children’s
Hospital, Division of Metabolism and Swiss Newborn Screening, Zu¨rich,
Switzerland
Background: Newborn screening (NBS) for cystic ﬁbrosis (CF) was introduced
in Switzerland on January 1st, 2011 as a pilot study for two years. It comprises
measurement of immunoreactive trypsinogen (IRT) followed by searching for the
7 most common DNA mutations in Switzerland.
Methods: To evaluate the NBS, we measured the initial IRT tests, recall rate,
number of children referred to a CF centre and number of conﬁrmed diagnoses.
Then, we calculated referral rate, current positive predictive value (PPV) and
incidence.
Results: Within one year, 85,588 IRT tests from approx. 82,700 life births were
performed; 0.76% of them (648/85,588) were positive, and DNA screening was
performed. In 439 children, a 2nd IRT test was necessary. In total, 85 children were
referred to a CF center for sweat testing. In 28 children (33%), the diagnosis of
CF could be conﬁrmed, and an additional child was clinically diagnosed having
meconium ileus with a normal IRT. 54 children (64%) had a negative sweat test,
and in two children, the diagnosis was not yet made (not yet fully investigated).
The recall rate for the 2nd IRT test was 0.51% (439/85,588), the referral rate to a
CF centre was 13.1% (85/648) and the PPV was 34.9% (29/83). The provisional
incidence rate was 1:2851 (29/82,700)
Conclusions: There were no major obstacles in the implementation of the NBS for
CF in Switzerland. The recall rate of 0.51% was lower than expected. One third
of patients referred for sweat tests were diagnosed with CF. The incidence rate of
1:2851 has to be interpreted with caution, as the exact birth rate and the deﬁnite
diagnosis of all children was not yet available at the time of writing this abstract.
